HealthcareA medical technology business typically supports 2.6x to 3.1x EBITDA of debt, depending on cash flow stability and existing commitments. Estimate your borrowing capacity in EUR below.
Based on middle-market lending data for Luxembourg. Actual terms vary based on company-specific factors.
Luxembourg facilities follow European market practice: leverage, debt-service and coverage tests with regular reporting, documented to European standards and calibrated to the sector's cash-flow profile. Medtech facilities typically pair leverage and coverage tests with monitoring of certification status, reflecting the regulatory foundation of the revenue being financed.
Complete the form below to get your personalized borrowing capacity analysis in EUR
Medical technology companies in Luxembourg borrow against portfolios whose value is regulatory as much as commercial: CE markings under the EU Medical Device Regulation, quality-management systems and clinical evidence underpin the revenue lenders finance. Export orientation is structural: the domestic market is too small to sustain a medtech business on its own, so multi-country revenue is the norm in every credit file.
Lenders weight recurring revenue heavily: consumables, service contracts and device-attached software support cash-flow structures that one-off device sales cannot. The distribution model (direct revenue versus distributor networks) is examined alongside, with contract terms and channel inventory reviewed.
Development and equipment investment fit the state-backed toolkit: SNCI financing, including innovation and equipment instruments, is available to qualifying Luxembourg companies, with Luxinnovation supporting qualifying innovation activity at the operating level.
Lenders monitor MDR certification status, expiry dates and post-market surveillance to assess whether regulatory issues could interrupt revenue. Lenders need current regulatory documentation alongside the financial model.
Luxembourg's banking market is concentrated among a small number of established institutions: Spuerkeess (BCEE), BGL BNP Paribas and BIL anchor domestic SME lending, alongside international banks and alternative lenders. Banks and authorised lending professionals are supervised by the CSSF; the regulatory status of other providers depends on their activities. The SNCI, the national development bank, provides medium and long-term financing directly or through commercial banks, and the Mutualité de Cautionnement can guarantee part of a facility where a borrower's own security is insufficient. Medtech borrowers are financed on regulatory position and recurring revenue, with appetite strongest where CE-marked portfolios generate consumables or service income.
Luxembourg facilities follow European market practice: leverage, debt-service and coverage tests with regular reporting, documented to European standards and calibrated to the sector's cash-flow profile. Medtech facilities typically pair leverage and coverage tests with monitoring of certification status, reflecting the regulatory foundation of the revenue being financed. Borrowers should track covenant headroom against a tested forecast.
The CSSF supervises banks and authorised lending professionals in Luxembourg, and EU banking regulation applies. Interest expense is generally deductible within EU-derived interest-limitation rules. For medical technology businesses, specific considerations include collateral documentation requirements, asset appraisal and equipment valuation processes, and compliance with local lending regulations. Financing support through the SNCI or a Mutualité de Cautionnement guarantee may improve terms for qualifying businesses.
Use our free valuation calculator to estimate your medical technology business worth in EUR.
Tell us what you're working on. We'll tell you how we'd approach it. We respond within 24 hours.
Perspectives on corporate finance, fundraising, and M&A, from the Alehar team.
United States
United Kingdom
United Arab Emirates
Saudi Arabia
India